Free Trial

Cypress Asset Management Inc. TX Invests $4.39 Million in Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. logo with Medical background

Cypress Asset Management Inc. TX bought a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 43,324 shares of the company's stock, valued at approximately $4,388,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. TI Trust Inc. raised its stake in shares of Merck & Co., Inc. by 0.6% during the 4th quarter. TI Trust Inc. now owns 19,834 shares of the company's stock worth $1,973,000 after buying an additional 111 shares in the last quarter. Hengehold Capital Management LLC raised its stake in shares of Merck & Co., Inc. by 0.3% during the 4th quarter. Hengehold Capital Management LLC now owns 39,989 shares of the company's stock worth $3,978,000 after buying an additional 112 shares in the last quarter. Peterson Wealth Services raised its stake in shares of Merck & Co., Inc. by 0.5% during the 4th quarter. Peterson Wealth Services now owns 21,479 shares of the company's stock worth $2,137,000 after buying an additional 113 shares in the last quarter. Hemington Wealth Management raised its stake in shares of Merck & Co., Inc. by 3.2% during the 4th quarter. Hemington Wealth Management now owns 4,050 shares of the company's stock worth $402,000 after buying an additional 125 shares in the last quarter. Finally, Center for Financial Planning Inc. raised its stake in shares of Merck & Co., Inc. by 0.9% during the 4th quarter. Center for Financial Planning Inc. now owns 14,805 shares of the company's stock worth $1,473,000 after buying an additional 125 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Down 0.1%

Shares of NYSE MRK traded down $0.08 during midday trading on Tuesday, reaching $77.50. 11,867,802 shares of the company's stock were exchanged, compared to its average volume of 12,568,652. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. The stock has a market capitalization of $194.60 billion, a PE ratio of 11.52, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $134.63. The business's fifty day moving average price is $81.43 and its two-hundred day moving average price is $91.15.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.06. The firm had revenue of $15.53 billion during the quarter, compared to analyst estimates of $15.59 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. Merck & Co., Inc.'s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.07 earnings per share. Analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. declared that its Board of Directors has approved a share buyback plan on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to purchase up to 4.1% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's leadership believes its stock is undervalued.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 8th. Investors of record on Monday, June 16th will be issued a $0.81 dividend. This represents a $3.24 annualized dividend and a yield of 4.18%. Merck & Co., Inc.'s dividend payout ratio is currently 47.16%.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, SVP Dalton E. Smart III sold 4,262 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $82.76, for a total value of $352,723.12. Following the completion of the transaction, the senior vice president now directly owns 7,778 shares in the company, valued at $643,707.28. The trade was a 35.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on MRK shares. Guggenheim reissued a "buy" rating and set a $115.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, April 17th. Bank of America cut their target price on Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating for the company in a research note on Wednesday, February 5th. TD Cowen downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating and dropped their price objective for the company from $121.00 to $100.00 in a research note on Monday, February 10th. BMO Capital Markets dropped their price objective on Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating for the company in a research note on Wednesday, February 5th. Finally, Citigroup reiterated a "neutral" rating and set a $84.00 target price (down previously from $115.00) on shares of Merck & Co., Inc. in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $109.19.

Read Our Latest Research Report on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Recommended Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines